Investment Opportunities.
U.S. Precision Medicine is currently seeking accredited investors to complete the pathway that will put a breakthrough patented cancer drug in the hands of the medical community via acquisition to a major pharma company.
Investment Opportunities.
-
TO DATE.
To date, independent research through invitro & invivo studies verifies that DH20931:
-- Provides n 80% reduction in cancer tumor volume
-- 85% reduction in growth
-- No toxicity
-
IN 12 MONTHS.
Funding will complete IND research in 12 months:
-- Additional research on dosage, combo studies with doxo and other cancer drugs for metastatic cancers
-- Manufacturing, quality management and safety plans, etc. for final FDA application
-
NEXT 8 to 12 MONTHS.
In the following 8 to 12 months, U.S. Precision Medicine will execute FDA Phase 1 before concluding a M&A via a major pharma partner or IPO.
Funding Details.
Contact for details:
Chris Fey
469-400-6522 Chris.Fey@uspm.global
Fred Fey
386-438-4979 Fred.Fey@uspm.global